» Articles » PMID: 19562761

Motor Abnormalities in Premanifest Persons with Huntington's Disease: the PREDICT-HD Study

Overview
Journal Mov Disord
Date 2009 Jun 30
PMID 19562761
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

The PREDICT-HD study seeks to identify clinical and biological markers of Huntington's disease in premanifest individuals who have undergone predictive genetic testing. We compared baseline motor data between gene-expansion carriers (cases) and nongene-expansion carriers (controls) using t-tests and Chi-square. Cases were categorized as near, mid, or far from diagnosis using a CAG-based formula. Striatal volumes were calculated using volumetric magnetic resonance imaging measurements. Multiple linear regression associated total motor score, motor domains, and individual motor items with estimated diagnosis and striatal volumes. Elevated total motor scores at baseline were associated with higher genetic probability of disease diagnosis in the near future (partial R(2) 0.14, P < 0.0001) and smaller striatal volumes (partial R(2) 0.15, P < 0.0001). Nearly all motor domain scores showed greater abnormality with increasing proximity to diagnosis, although bradykinesia and chorea were most highly associated with diagnostic immediacy. Among individual motor items, worse scores on finger tapping, tandem gait, Luria, saccade initiation, and chorea show unique association with diagnosis probability. Even in this premanifest population, subtle motor abnormalities were associated with a higher probability of disease diagnosis and smaller striatal volumes. Longitudinal assessment will help inform whether motor items will be useful measures in preventive clinical trials.

Citing Articles

Refining the Language of Huntington's Disease Progression with the Huntington's Disease Integrated Staging System (HD-ISS).

Sampaio C, Kostyk S, Tabrizi S, Rosser A J Huntingtons Dis. 2024; 13(2):115-118.

PMID: 38968053 PMC: 11307057. DOI: 10.3233/JHD-240043.


White Matter Microstructure Changes Revealed by Diffusion Kurtosis and Diffusion Tensor Imaging in Mutant Huntingtin Gene Carriers.

Yin J, Liu Y, Li H, Burgunder J, Huang Y J Huntingtons Dis. 2024; 13(3):301-313.

PMID: 38905054 PMC: 11494636. DOI: 10.3233/JHD-240018.


Cognitive reserve involves decision making and is associated with left parietal and hippocampal hypertrophy in neurodegeneration.

Le Stanc L, Lunven M, Giavazzi M, Sliwinski A, Youssov K, Bachoud-Levi A Commun Biol. 2024; 7(1):741.

PMID: 38890487 PMC: 11189446. DOI: 10.1038/s42003-024-06416-x.


Postmortem neuropathology in early Huntington disease.

Hedreen J, Berretta S, White Iii C J Neuropathol Exp Neurol. 2024; 83(5):294-306.

PMID: 38553027 PMC: 11029463. DOI: 10.1093/jnen/nlae022.


"I don't have Huntington's disease": the boundaries between acceptance and understanding.

Franklin G, Teive H, Cardoso F Arq Neuropsiquiatr. 2023; 81(7):696-699.

PMID: 37494950 PMC: 10371396. DOI: 10.1055/s-0043-1768158.


References
1.
Duff K, Paulsen J, Beglinger L, Langbehn D, Stout J . Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007; 62(12):1341-6. DOI: 10.1016/j.biopsych.2006.11.034. View

2.
Langbehn D, Brinkman R, Falush D, Paulsen J, Hayden M . A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004; 65(4):267-77. DOI: 10.1111/j.1399-0004.2004.00241.x. View

3.
Aylward E, Sparks B, Field K, Yallapragada V, Shpritz B, Rosenblatt A . Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology. 2004; 63(1):66-72. DOI: 10.1212/01.wnl.0000132965.14653.d1. View

4.
. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996; 11(2):136-42. DOI: 10.1002/mds.870110204. View

5.
Gomez-Tortosa E, Macdonald M, Friend J, Taylor S, Weiler L, Cupples L . Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol. 2001; 49(1):29-34. View